1. The compound of Formula I or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer or tautomer thereof, wherein X is halogen； Z1 and Z2 are independently and separately CR2 or N； Z3 is CH or N； provided that ring B is not tetrazine ； each R1 is independently and separately halogen, H, C1-C6 alkyl, branched C3-C7 alkyl, C3-C7 cycloalkyl or -CN； each R2 is individually and independently H, halogen, C1-C6 alkyl or cyano； R3 is - C (O) R4, -C (O) -C6-C10-aryl, -C (O) -C4-C6-heterocyclyl, or -C (O) -C5-C6-heteroaryl, where aryl is I phenyl, naphthyl, tetrahydronaphthyl, indenyl or indanyl； and provided that if R3 is -C (O) -C4-C6 heterocyclyl, then this heterocyclyl does not have N linked to -C (O)； R4 is C1-C7 alkyl, C3-C8 cycloalkyl, - (CH) -CN, - (CH) -OR6, - (CH) -NR6 (R7), - (CH) SO-C1-C6-alkyl, - (CH) -C6-C10-aryl, - (CH) -C5- C6-heteroaryl or - (CH) -C4-C6-heterocyclyl, wherein each alkyl or alkylene is optionally substituted with one or two C1-C6 alkyls； aaryl is phenyl, naphthyl, tetrahydronaphthyl, indenyl or indanyl； each R6 and R7 is independently and independently H, C1-C6 alkyl or C3-C8 branched alkyl； each cycloalkyl, aryl, heteroaryl and heterocyclyl is independently substituted - (R25)； each R25 separately and independently, is C1-C6 alkyl, branched C3-C8 alkyl, halogen, - (CH) -CN, - (CH) -OR6, - (CH) -NR6 (R7), - (CH) -SO-C1- C6-alkyl, - (CH) -C (O) NR6 (R7), - (CH) -C (O) -C4-C6-heterocyclyl or (CH) -C4-C6-heterocyclyl, where each alkyl or alkylene is optional substituted by one or two C1-C6 alkyls； each m separately and independently isimo is 0, 1, 2 or 3； ir equals 1, 2 or 3.2. The compound according to claim 1, characterized in that Z1 and Z2 are CR2, and Z3 is CH.3. The compound according to claim 2, characterized1. Соединение Формулы Iили его фармацевтически приемлемая соль, гидрат, сольват, энантиомер, стереоизомер или таутомер,гдеX является галогеном；Z1 и Z2 независимо и отдельно являются CR2 или N；Z3 является СН или
